Canada’s Drug Agency (CDA-AMC)
In December 2023, it was announced that Canada’s Drug Agency would be built from CADTH. The work of the drug agency expands on CADTH’s existing mandate and functions — which spans drugs, medical devices, and clinical interventions — and includes new work streams such as:
- improving the appropriate prescribing and use of medications
- increasing pan-Canadian data collection and expanding access to drug and treatment data, including real-world evidence data
- reducing drug system duplication and lack of coordination
CADTH adopted the new name Canada’s Drug Agency (CDA-AMC) as of May 1, 2024. An official launch will occur later this year.
CCRA Exceptional Leadership in Cancer Research Award to be Renamed
Effective October 9, 2024, the CCRA Advisory Board voted to modify the Exceptional Leadership in Cancer Research to the “Philip E. Branton Award for Exceptional Leadership in Cancer Research” to acknowledge and recognize Dr. Branton’s pivotal role in the creation of CCRA and his extraordinary contribution to Canada’s cancer research community. Dr. Branton was the inaugural recipient of this award when the program was initiated in 2011.
Dr. Branton obtained his PhD from the Ontario Cancer I... Read More »
Clinical Research Fellow Opportunity
The Princess Margaret Cancer Centre's Gynecology Medical Oncology team is accepting applications for the position of Clinical Research Fellow in the Bras Drug Development Program under the supervision of Dr. Amit Oza. The Bras Family New Drug Development Program ... Read More »
The Princess Margaret Cancer Centre's Gynecology Medical Oncology team is accepting applications for the position of Clinical Research Fellow in the Bras Drug Development Program under the supervision of Dr. Amit Oza. The Bras Family New Drug Development Program ... Read More »